Glandular cell neoplasm

This early-stage study tested a vaccine called DCP-001 in 17 women with a serious type of ovarian cancer who had already completed standard treatment. The goal was to see if the vaccine is safe and can boost the immune system to recognize and fight cancer cells. Researchers measu…

This study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.

This study tests whether a combination of ramucirumab plus FOLFIRI (a standard chemo regimen) works better than ramucirumab plus paclitaxel for people with advanced stomach or gastroesophageal junction cancer that has worsened after one prior chemo treatment. About 429 participan…

This study tests whether giving a three-part treatment before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. The treatment combines an immunotherapy drug (tislelizumab) with standard chemotherapy and a short course of ra…

This study tests a type of radiation called high-dose brachytherapy for men with prostate cancer that hasn't spread. Doctors place tiny radioactive sources directly into the prostate to deliver a strong dose to the tumor while sparing nearby healthy tissue. The goal is to control…

This phase II trial tests the drug lenalidomide (CC-5013) in people with advanced or inoperable kidney cancer. Lenalidomide works by cutting off blood flow to tumors, which may stop or slow their growth. The study aims to see how many patients respond to treatment and what side e…

This trial investigates whether adding antroquinonol (Hocena) to standard chemotherapy (nab-paclitaxel and gemcitabine) can safely treat people with metastatic pancreatic cancer that has not yet been treated. The study has two phases: first, finding the best dose, and second, che…

This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…

This phase 2 trial is testing a new drug called cadonilimab (AK104), either alone or combined with axitinib, as a first treatment for advanced or metastatic kidney cancer. The study includes two parts: one testing different doses of cadonilimab alone in various kidney cancer type…

This early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…

This study tested whether two drugs, zanidatamab and evorpacept, are safe and can shrink tumors in people with advanced HER2-expressing cancers. Fifty-two patients with breast or other cancers that had spread or couldn't be removed by surgery took part. The goal was to see how ma…

This study tests a two-pronged chemotherapy approach for people with intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be removed by surgery. Participants receive chemotherapy directly to the liver through a surgically placed pump, plus standard chemotherap…

This early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This pilot study tests whether a purified green tea extract called EGCG can help prevent colon cancer from coming back after surgery. 51 patients who had their colon cancer removed took either the extract or a placebo. Researchers are checking for changes in DNA methylation, a ma…

This study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if d…

This study tests whether adding a targeted drug (Donafenib) and chemotherapy directly into the liver's blood supply can prevent liver cancer from returning after surgery. It includes adults with a single large tumor (≥5 cm) and microscopic blood vessel invasion, who are at high r…

This study tests a treatment plan tailored to each child's risk level for a rare liver cancer called hepatoblastoma. About 236 children will receive standard treatments like surgery and chemotherapy, plus the drug temsirolimus for high-risk cases. The goal is to see if this appro…

This clinical trial is testing a combination of two drugs—an immunotherapy (pembrolizumab/quavonlimab) and a targeted therapy (lenvatinib)—as a first treatment for people with advanced hepatocellular carcinoma, a type of liver cancer that cannot be removed by surgery. The study a…

This trial investigates whether giving two immunotherapy drugs, ipilimumab and nivolumab, before liver surgery can help shrink tumors in people with liver cancer (hepatocellular carcinoma). Participants receive the drugs in the weeks leading up to their planned surgery. The study…

This study tests whether giving patients their own stool bacteria through a temporary stoma can reduce inflammation in the unused part of the colon, a condition called diversion colitis. Sixty-six people with rectal cancer who have a temporary ileostomy will receive either a dail…

This study tested a two-step treatment for medium-sized kidney tumors (4.1-7 cm). First, doctors blocked the tumor's blood supply, then froze it. The goal was to see if this approach is safe and works well. 25 adults with stage T1b kidney cancer took part. The main focus was on s…

This study looks at whether removing a small, low-grade breast change called DCIS with surgery alone is enough. About 158 people with grade 1 or 2 DCIS are being followed to see if the condition comes back. The goal is to find out if some patients can avoid additional treatments …

This phase 2 trial tested whether adding an experimental drug called SRF388 to a standard two-drug regimen (atezolizumab plus bevacizumab) helps people with advanced liver cancer that hasn't been treated before. The study enrolled 30 adults whose cancer could not be surgically re…

This early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …

This early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…

This phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment …

This phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…

This phase 2 trial tested phenelzine sulfate (Nardil), an antidepressant, in 26 men with prostate cancer that returned after initial treatment but hadn't spread. The goal was to see if the drug could lower PSA levels, a marker of cancer activity. Researchers measured how many pat…

This large phase III trial studied whether adding the targeted drug cetuximab to standard chemotherapy after surgery helps prevent cancer from coming back in patients with stage III colon cancer. Over 3,300 patients took part, and the study focused on those with a specific geneti…

This early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…

This study tested whether giving a mix of immunotherapy drugs (tislelizumab and IL-2) plus chemotherapy before surgery could shrink tumors more effectively in people with locally advanced rectal cancer. The trial involved 130 adults whose cancers had not spread but were hard to t…

This study tested whether adding the chemotherapy drug doxorubicin to the targeted therapy sorafenib helps people with advanced liver cancer live longer. Over 350 patients received either sorafenib alone or sorafenib plus doxorubicin. The main goal was to compare overall survival…

This completed trial tested whether a daily EPA (an omega-3 fatty acid) supplement could help preserve muscle mass and reduce inflammation in 18 people with advanced liver cancer that could not be surgically removed. Participants took either the EPA supplement or a placebo for 12…

This large phase 3 trial tested whether taking sorafenib or sunitinib after kidney cancer surgery could prevent the cancer from coming back. Nearly 2000 patients participated. Unfortunately, neither drug improved disease-free survival compared to a placebo, and they caused side e…

This phase 1 trial tested the drug AL101 in 13 people with a rare salivary gland cancer called adenoid cystic carcinoma that has a specific genetic change (notch activation). Participants received AL101 before their standard surgery to see if it is safe and might help control the…

This early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…

This Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…

This study looked at 612 men with prostate cancer that had been removed by surgery. It compared standard treatment (hormone therapy plus radiation) against the same treatment plus the chemotherapy drug docetaxel. The goal was to see if adding chemo helps keep the cancer from comi…

This study looked at whether giving heated chemotherapy directly into the abdomen during a second-look surgery is possible for people with ovarian, fallopian tube, or peritoneal cancer. Ten participants who had already received standard treatment were enrolled. The goal was to se…

This study tested whether giving a higher dose of radiation specifically to the visible tumor inside the prostate could improve cancer control in men with localized prostate cancer. Eighty-five men either received a standard radiation plan with an extra boost to the tumor or a co…

This study tested a new type of PET/MRI scan that uses a special tracer to find small spots of prostate cancer that standard scans miss. Men with a rising PSA after prostate surgery and radiation received targeted radiation to those spots. The goal was to see if this approach can…

This trial compares two types of surgery for pancreatic cancer in the body or tail of the pancreas: minimally invasive (laparoscopic or robot-assisted) versus traditional open surgery. The goal is to see if the less invasive approach can remove the tumor just as completely. Adult…

This study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This study tested a combination of two experimental treatments for people with advanced kidney cancer that cannot be removed by surgery. The first is Pexa-Vec, a modified virus designed to infect and destroy cancer cells while also boosting the immune system. The second is cemipl…

This Phase II trial tested a combination of chemotherapy drugs (FOLFIRINOX) plus the blood pressure drug losartan, followed by proton radiation, in 50 people with locally advanced pancreatic cancer. The goal was to see if this approach could shrink tumors enough to allow complete…

This early-phase trial tested a new approach for advanced liver cancer that has not responded to standard treatments. Researchers took participants' own immune cells, modified them in a lab to target a protein called AFP found on cancer cells, and infused them back after a short …

This study tests whether a combination of three drugs—cisplatin, nivolumab, and temozolomide—can shrink tumors in people with advanced colorectal cancer that has not responded to other treatments. The cancer must be a specific type called MMR-proficient. The trial involves 18 par…

This early-phase trial tested a new drug called RO7496353 combined with an immunotherapy (atezolizumab) and sometimes chemotherapy in 102 people with advanced lung, stomach, or pancreatic cancer. The main goal was to check safety and side effects. Researchers also looked at how t…

This study tested whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence were randomly assigned to receive the drug co…

This trial tested a new treatment called EGFR BATs for people with advanced pancreatic cancer. The treatment uses a patient's own immune cells, armed with a special antibody, to target cancer cells. The study included 22 participants who had already received chemotherapy. The goa…

This completed study looked at how well avelumab (BAVENCIO) plus axitinib (INLYTA) works for advanced kidney cancer in everyday medical practice. Researchers tracked 105 patients across multiple EU countries to see survival rates at 12 and 24 months. The goal was to understand th…

This phase 2 trial tested a modified virus called JX-594 (Pexa-Vec) in 30 people with liver cancer that could not be surgically removed. The virus was injected directly into the liver tumors to see if it could stop the cancer from growing. Researchers measured how many patients h…

This study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…

This pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …

This phase II trial tested a combination of two targeted antibodies (pertuzumab and trastuzumab) plus a chemotherapy drug (nab-paclitaxel) in 63 patients with HER2-positive advanced breast cancer. The goal was to see how well the drugs work together to stop tumor growth and impro…

This small, completed phase II study tested the safety of combining two drugs—atezolizumab (an immunotherapy) and bevacizumab (a blood vessel blocker)—in 6 people with advanced liver cancer who also had moderate cirrhosis (Child-Pugh B7 or B8). The goal was to see if this treatme…

This early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…

This study looked at 715 patients with very large liver cancers (over 10 cm) to see if giving a combination of local treatments (like chemo directly into the liver) and body-wide treatments (targeted drugs and immunotherapy) before surgery helps them live longer. Patients were di…

This phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…

This study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…

This phase 3 trial tested whether a combination of two drugs, regorafenib and nivolumab, helps people with advanced gastro-oesophageal cancer live longer than standard chemotherapy. The study included 462 adults whose cancer had stopped responding to prior treatments. The goal wa…

This study tested a new way to reconnect the stomach and small intestine after removing the lower part of the stomach in people with advanced stomach cancer. The goal was to see if the new stapling method was safe and worked well. One hundred patients took part, and the researche…

This phase 2 trial tested whether adding an immunotherapy drug called botensilimab to standard chemotherapy could help people with metastatic pancreatic cancer who had already progressed on a common chemo regimen (FOLFIRINOX). The study enrolled 81 participants and compared the c…

This early-phase trial tested a new approach for people with advanced head and neck cancer that has come back or spread. It combined specially trained natural killer (NK) immune cells with drugs that help the immune system attack cancer. The study enrolled 11 participants to chec…

This early-phase study tested an experimental drug called APX005M added to two standard immunotherapies (nivolumab and ipilimumab) in 26 people with advanced melanoma or kidney cancer who had not received prior immune therapy. The main goals were to check safety and find the best…

This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …

This study tested a combination of two drugs, cadonilimab and regorafenib, in 36 adults with advanced liver cancer that had worsened after standard treatments. The goal was to see if the combo could slow cancer growth and how safe it was. Results may help develop better options f…

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This trial studies whether breast-conserving surgery (lumpectomy) followed by radiation is a safe and effective option for women aged 40 and older who have two or more breast cancer tumors in the same breast. The goal is to see if this less invasive approach can control the cance…

This study tested whether adding a virus-based immunotherapy (Pexa-Vec) to the standard drug sorafenib helps people with advanced liver cancer live longer. About 459 adults with advanced liver cancer who had not received prior treatment took part. The approach uses a modified vir…

This phase 2 trial tested personalized immunotherapy combinations for advanced gastric cancer that had worsened after initial chemotherapy. Researchers matched treatments to tumor genetics: patients with certain genetic features received atezolizumab plus ipatasertib, while other…

This early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…

This study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…

This phase 2 trial tested a combination of radiation, a targeted drug (olaparib), and an immunotherapy (pembrolizumab) in 9 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if this approach could shrink tumors that were not dir…

This completed phase 4 trial tested whether adding SB Flavon (a blend of flavonoids, vitamin C, and L-arginine) to standard Tenofovir therapy can reverse advanced liver scarring (cirrhosis) and prevent liver cancer in 134 people with chronic hepatitis B. The study measured liver …

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…

This phase 2 study tested a combination of two drugs, pembrolizumab and ramucirumab, in 26 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if the combo could shrink tumors or slow the disease. Participants received both drugs …

This study tested a combination of two drugs (atezolizumab and bevacizumab) given before surgery to people with liver cancer. The goal was to see how well the drugs shrink the tumor and how they affect the immune system. 40 participants were enrolled, and researchers also studied…

This phase III trial tested whether adding trastuzumab (Herceptin) to standard chemotherapy and radiation helps people with HER2-positive esophageal cancer. 203 patients were randomly assigned to get chemo and radiation with or without trastuzumab. The study measured how long pat…

This phase 2 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 patients with aggressive pituitary tumors that worsened after surgery and radiation. The goal was to see if the combination could shrink tumors or slow their growth. Researchers also monitored side…

This trial tested a three-drug combination—chemotherapy infused into the liver, an immunotherapy drug (tislelizumab), and a targeted pill (regorafenib)—as a first treatment for 31 people with advanced bile duct cancer that couldn't be removed by surgery. The goal was to see how m…

This phase 2 trial tested two drugs, osimertinib and gefitinib, in 156 people with advanced EGFR-mutant lung cancer. The goal was to see if using blood tests (liquid biopsies) to detect genetic changes could help decide when to switch treatments, compared to standard scans. The s…

This study looked at the safety of two drugs, IMJUDO and IMFINZI, given together or alone to 1,200 people with advanced liver cancer that cannot be removed by surgery. The main goal was to track any side effects that happen in everyday medical use. The study is now complete and h…

This phase III trial tested whether adding a monoclonal antibody called edrecolomab to surgery helps people with stage II colon cancer live longer or stay cancer-free longer. About 2,100 participants were randomly assigned to receive either the antibody or no additional treatment…

This study observed 311 adults with advanced kidney cancer who received cabozantinib (a targeted therapy) plus nivolumab (an immunotherapy) as their first treatment. Researchers tracked how long patients lived and how long tumors stayed under control in real-world settings. The g…

This phase II trial tested a combination of three treatments: specially engineered natural killer cells (PD-L1 CAR-NK cells), an immunotherapy drug (pembrolizumab), and an immune booster (N-803) in 18 adults with advanced gastric or head and neck cancer that had not responded to …

This large Phase III trial tested whether adding the drug bevacizumab to chemotherapy works better when the chemo is given into a vein (IV) or directly into the belly (IP). It involved 1560 people with advanced ovarian, fallopian tube, or peritoneal cancers. The goal was to see w…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This early-phase trial tested a new drug called SRG-514 in 25 people undergoing breast-conserving surgery for breast cancer. The drug was given directly into the area where the tumor was removed. The main goal was to find a safe dose and check for side effects. This is a first st…

This completed phase 1/2 trial tested an experimental drug called Y101D combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for 71 people with advanced pancreatic cancer. The goal was to find a safe dose and see if the combo helps shrink tumo…

This study tested whether adding a Chinese herbal formula (QingyiHuaji) to standard chemotherapy helps people with stage IV pancreatic cancer live longer. About 305 adults with advanced pancreatic cancer were randomly assigned to receive either the herbal formula plus chemo or a …

This phase 3 trial tested whether adding a targeted drug called bemarituzumab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer that has a specific protein (FGFR2b). The study enrolled 547 adults whose cancer could not be removed by s…

This early-phase trial tested a shorter course of radiation for men whose prostate cancer came back after their prostate was removed. Instead of the usual 6-7 weeks of daily radiation, researchers gave higher doses over just 2-4 weeks, focusing the strongest radiation on the tumo…

This early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…

This phase 3 trial compared a combination of two immunotherapy drugs (nivolumab and ipilimumab) against the standard drug sunitinib in over 1,000 people with untreated advanced or metastatic kidney cancer. The study measured how well the tumors shrank, how long patients lived wit…

This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…

This phase II trial tested a shorter course of higher-dose radiation (hypofractionation) in 53 men with high-risk prostate cancer who had already had their prostate removed. The goal was to see if this approach could control cancer while reducing side effects. Participants also r…

This Phase 3 trial tested a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard treatments (regorafenib or TAS-102) in 441 people with advanced colorectal cancer that had stopped responding to prior therapy. The goal was to see if the new combin…

This study tested a combination of chemotherapy infused into the liver artery plus two drugs (camrelizumab and apatinib) in 21 people with liver cancer that could not be surgically removed. The goal was to shrink the tumors enough to allow surgery. The study is complete, and resu…

This study looked at whether adding metformin (a common diabetes medicine) to standard chemotherapy and radiation helps people with stage III non-small cell lung cancer live longer without their cancer getting worse. About 170 adults with advanced lung cancer took part. The goal …

This study tested a new drug called gentuximab combined with the chemotherapy drug paclitaxel in 76 people with advanced stomach or gastroesophageal junction cancer that had worsened after initial treatment. The goal was to find a safe and effective dose and see if the combinatio…

This early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…

This early-stage trial tested a drug called belzutifan in 29 people with advanced clear cell kidney cancer that had worsened after other treatments. The main goal was to check safety and find the right dose. Participants took belzutifan pills daily, and researchers monitored side…

This study followed 354 men with low- to intermediate-risk prostate cancer who chose to freeze only the cancerous half of their prostate (hemi-gland cryoablation). Researchers tracked how well the treatment controlled the cancer and how it affected urinary function and quality of…

This Phase 3 trial tested whether combining pembrolizumab (an immunotherapy) with epacadostat (a drug that boosts the immune response) works better than standard drugs (sunitinib or pazopanib) for people with advanced kidney cancer that hasn't been treated before. The study enrol…

This study tested a new drug called NIS793 added to standard chemotherapy for people with metastatic pancreatic cancer that has spread. The goal was to see if the combination could help patients live longer by reducing scar tissue in the tumor. About 511 adults with this advanced…

This phase 2 trial tested whether adding the drug veliparib to standard chemotherapy (FOLFIRI) helps people with metastatic pancreatic cancer live longer. 123 patients whose cancer had returned after initial treatment were randomly assigned to get FOLFIRI alone or FOLFIRI plus ve…

This study tested a personalized vaccine made from a patient's own tumor cells fused with immune cells (dendritic cells) to treat stage IV kidney cancer. The vaccine was given with a drug called GM-CSF to boost immune response. The main goal was to check safety and side effects i…

This study tested whether a shorter course of higher-dose radiation (hypofractionated) works as well as standard radiation after prostate removal in 296 men with prostate cancer. The main focus was on quality of life, especially urinary and bowel function. The goal is to find a t…

This study tested a new X-ray monitoring technique (KIM) during prostate cancer radiation therapy. The goal was to see if it helps doctors aim more precisely at the tumor while reducing harm to healthy tissue. 49 men with low- or intermediate-risk prostate cancer took part. The a…

This study tested whether adding the drug niraparib to standard radiation and hormone therapy can help prevent high-risk prostate cancer from coming back. Niraparib blocks a protein that cancer cells use to repair their DNA, which may kill them. The trial enrolled 22 men with agg…

This study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…

This early-phase trial tested whether adding a new drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe and could help shrink tumors in people with locally advanced pancreatic cancer that cannot be removed by surgery. 43 participants received the combination. The main…

This early-phase study tested a new treatment called JX-594, a modified virus injected directly into liver tumors. The goal was to find the safest dose and see if it could shrink tumors in 14 patients with advanced liver cancer that had not responded to standard treatments. The s…

This phase I trial tested a new type of radiation therapy for low- and intermediate-risk prostate cancer that delivers a higher dose each day, completing treatment in just 5 sessions over 2 weeks instead of the usual 45-48. The study enrolled 120 participants to check the safety …

This phase 2 trial tested a two-step treatment for advanced esophageal cancer that has a specific genetic marker (MGMT deficiency) and has stopped responding to standard chemotherapy. First, patients took a daily oral chemotherapy drug (temozolomide) for three months. Then, they …

This pilot study tested a combination of chemotherapy drugs (FOLFIRINOX plus paclitaxel and carboplatin) along with proton beam radiation before surgery in 25 people with gastroesophageal cancer. The goal was to see if this intense pre-surgery treatment could shrink tumors and be…

This phase 2 trial tested a combination of four chemotherapy drugs—irinotecan liposome, oxaliplatin, 5-fluorouracil, and levoleucovorin—in 41 Japanese adults with metastatic pancreatic cancer who had not received prior treatment. The goal was to see how well the drugs shrank tumo…

This study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…

This registry followed 152 patients with colorectal cancer that had spread mainly to the liver. Doctors used tiny beads called LifePearl Microspheres loaded with the chemotherapy drug irinotecan, delivered directly to the liver's blood supply. The goal was to see how and when thi…

This study tested whether placing a temporary drain in the pelvis after rectal cancer surgery reduces the risk of serious infections like leaks or abscesses. About 500 patients were randomly assigned to receive a drain or not. The main goal was to see if drainage lowered pelvic s…

This study tested a combination of Y90 radioembolization (a targeted radiation treatment for the liver) and nivolumab (an immunotherapy drug) in 40 Asian patients with advanced liver cancer that could not be surgically removed. The goal was to see if the combination could shrink …

This study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…

This study tested whether adding two experimental drugs (TTX-030 and budigalimab) to standard chemotherapy could help people with metastatic pancreatic cancer live longer without their disease getting worse. 194 adults who had not yet received treatment for their advanced cancer …

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…

This study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control appr…

This phase 3 trial tested whether adding two months of Folfirinox chemotherapy before standard radiation and chemo could help more patients with early-stage rectal cancer avoid major surgery. 218 adults with small, low-lying tumors were enrolled. The goal was to see if more patie…

This study tested the drug sunitinib (Sutent) in 71 people with advanced thyroid cancer that had spread or could not be removed by surgery. The goal was to see if the drug could shrink tumors when standard treatments like radioactive iodine no longer work. Participants took sunit…

This study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…

This study tested a drug called savolitinib in 110 people with advanced stomach or esophagus-stomach junction cancer whose tumors have a specific genetic change (MET gene amplification). The goal was to see if the drug could shrink tumors and how safe it was. Participants receive…

This early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…

This early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …

This early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…

This study tested a combination of three drugs (nivolumab, BMS-813160, and GVAX) in 22 people with locally advanced pancreatic cancer who had already received chemotherapy and radiation. The goal was to see if the treatment was safe and could help the immune system better attack …

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This study tested a new way to give radiation therapy for prostate cancer. It used very precise, high-dose radiation over just five days. The goal was to control the cancer while reducing side effects on the bladder and bowel. 444 men with localized prostate cancer took part, and…

This completed study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard immunotherapy and anti-angiogenesis drugs improves outcomes for people with advanced liver cancer that has spread into the portal vein. Over 1,600 participants were included. The …

This study tested a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that had stopped responding to standard targeted pills. The trial enrolled 95 adults and gave them two different combinations of immunotherapy (atezolizum…

This study looked at adding a procedure called TACE (which blocks blood flow to tumors) to a mix of immunotherapy and anti-angiogenesis drugs for people with advanced liver cancer that has invaded major blood vessels. Over 2,600 participants were included to see if the triple com…

This study tested a combination of three chemotherapy drugs (paclitaxel protein bound, gemcitabine, and cisplatin) in 34 people with metastatic pancreatic cancer that had not been treated before. If the cancer got worse, a fourth drug (paricalcitol) was added. The goal was to see…

This study tested whether adding an immunotherapy drug (nivolumab) to a targeted therapy (tivozanib) helps people with advanced kidney cancer live longer without their cancer growing. The trial included 343 adults whose cancer had worsened after one or two prior treatments, inclu…

This study tested a treatment plan for locally advanced rectal cancer that uses a short course of radiation followed by chemotherapy, aiming to avoid surgery. 39 patients were enrolled. The goal was to see if the cancer could be completely controlled without an operation, using a…

This early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…

This study tested whether adding the immunotherapy drug spartalizumab to standard chemotherapy (FLOT) helps shrink stomach cancer before surgery and prevent it from coming back. 67 adults with resectable stomach or gastroesophageal junction cancer received the combination before …

This early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…

This early-phase study tested a drug called itacitinib in 19 adults with advanced liver cancer that had not responded to first-line treatment. The goal was to check the drug's safety and see if it could shrink tumors or slow cancer growth. Itacitinib works by blocking a protein t…

This phase 1 trial tested a personalized vaccine made from each patient's unique cancer mutations (neoantigens) combined with an immune booster (poly-ICLC) in 33 people with pancreatic cancer. The vaccine was given after standard chemotherapy, either before or after surgery. The …

This study tested whether adding an immunotherapy drug called APX005M to standard treatment helps people with advanced rectal cancer achieve a complete response (no cancer left after treatment). 58 adults with stage II or III rectal cancer at high risk took part. The goal was to …

This trial tested a combination of two drugs—axitinib (a standard kidney cancer drug) and seleniomethionine (a form of selenium)—in 45 adults with advanced clear cell renal cell carcinoma that had spread. The goal was to find the safest dose and see if the combination could shrin…

This study tested a new way to give radiation to people with early-stage breast cancer. Instead of many sessions, patients received just three doses aimed only at the tumor area. The goal was to see if this shorter treatment is safe and works well. 77 patients took part, and the …

This phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

This early-phase study tested the safety of combining the immunotherapy drug pembrolizumab with precise, high-dose radiation (SBRT) to the liver in 15 adults with colorectal cancer that had spread only to the liver. The goal was to see if this combination could prevent the cancer…

This study tested whether a short course of radiation followed by chemotherapy could eliminate the need for surgery in people with early-stage rectal cancer. 63 patients were enrolled, and the treatment aimed for a complete clinical response, meaning no tumor could be found on ex…

This study tested whether giving radiotherapy to liver cancer patients with limited tumor growth (oligo progression) could delay the need for second-line drug therapy. Thirty-six adults with advanced hepatocellular carcinoma received targeted radiation. The goal was to see if thi…

This study looked at whether playing active video games (exergaming) and following a Mediterranean diet could help people who had their thyroid removed due to cancer. 80 adults were split into four groups: one did exergaming, one followed the diet, one did both, and one had no ex…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This pilot study tested a wearable device that delivers low-intensity electric fields (TTFields) together with immunotherapy (atezolizumab) and two chemotherapy drugs (gemcitabine and nab-paclitaxel) in 84 people with metastatic pancreatic cancer who had not received prior treatm…

This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…

This study tested a new drug, farletuzumab ecteribulin, which targets a protein found on many ovarian cancer cells. It was compared to standard chemotherapy in 106 women whose ovarian cancer had stopped responding to platinum-based treatments. The goal was to see if the new drug …

This study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …

This early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…

This phase 3 trial tested whether combining sotorasib (a pill) and panitumumab (an infusion) can slow tumor growth better than standard chemotherapy in 160 adults with metastatic colorectal cancer that has a specific KRAS G12C mutation. Participants were randomly assigned to rece…

This phase 3 trial tested whether adding lenvatinib and pembrolizumab to standard chemotherapy helps people with advanced gastroesophageal cancer live longer. About 895 participants received either the new combination or chemo alone. The study is complete, and results will show i…

This study tested a combination of four drugs (tadalafil, pembrolizumab, ipilimumab, and CRS-207) in 17 people with advanced pancreatic cancer that had worsened after at least one round of chemotherapy. The goal was to see if the combination was safe and could shrink tumors. The …

This study tested whether customizing chemotherapy based on specific gene mutations (EGFR and BRCA1) could improve outcomes for 153 patients with advanced lung adenocarcinoma. Participants received treatments matched to their tumor's genetic profile. The goal was to see if this p…

This trial tested several targeted drugs in people with non-small cell lung cancer whose tumors had specific genetic changes. The goal was to see if these drugs could shrink tumors or delay cancer growth. Over 400 participants received treatment based on their tumor's genetic pro…

This early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…

This phase 2 study tested the immunotherapy drug prolgolimab in 30 people with a specific type of colorectal cancer (MSI/dMMR) that had not spread. Participants received the drug for 6 months before planned surgery. The main goal was to see if the cancer completely disappeared in…

This study tested whether adding a radioactive drug (radium-223) to standard targeted radiation (SBRT) can delay cancer progression in men whose prostate cancer has returned in a few bone spots but hasn't yet become hormone-resistant. Twelve men participated, receiving either the…

This phase II trial tested whether combining two drugs, pembrolizumab and olaparib, could help people with persistent or recurrent endometrial cancer or carcinosarcoma. The study enrolled 26 participants and looked at how many responded to treatment and what side effects occurred…

This early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…

This study tested a new treatment for people with advanced clear cell kidney cancer that had spread and stopped responding to standard therapies. Six adults received four injections of a radioactive drug (177Lu-PSMA-1) that targets cancer cells. The goal was to check safety and s…

This large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) can prevent liver cancer from coming back in people who had successful surgery or ablation. 959 participants received either pembrolizumab or a placebo every three weeks. The study measured ho…

This early-phase study tested a combination of two drugs, cabozantinib and TAS-102, in 15 people with advanced colorectal cancer that had spread and stopped responding to standard treatments. The main goal was to find the safest dose and identify side effects. The study is comple…

This study tested whether a 3-year physical activity program could help prevent colon cancer from coming back in 889 patients who had surgery and chemotherapy for high-risk stage II or stage III colon cancer. Participants were randomly assigned to either the exercise program plus…

This study tested a combination of proton beam radiotherapy followed by two drugs (Tecentriq and Avastin) in 63 adults with advanced liver cancer that had spread into the portal vein. The goal was to see if this approach could help control the cancer and improve survival. Partici…

This study tested a newer, less invasive surgery called ETAP (done through the anus) against standard laparoscopic surgery (done through the belly) for low rectal cancer. 226 adults took part. The goal was to see if ETAP is as good at removing all cancer while possibly leading to…

This early-phase study tested a combination of three drugs (gemcitabine, capecitabine, and erlotinib) in 30 people with advanced pancreatic cancer that had already been treated. The main goal was to find the safest dose and understand side effects. This is not a cure, but aims to…

This study tested a combination of four drugs (paclitaxel protein bound, gemcitabine, cisplatin, and paricalcitol) given before surgery to people with pancreatic cancer that could or could not be removed. The goal was to see if the treatment could shrink tumors and improve surgic…

This completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…

This phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…

This study tested a combination of two drugs (cadonilimab and lenvatinib) given before surgery to 39 people with kidney cancer that was difficult to operate on while saving the kidney. The goal was to shrink the tumor enough to allow a partial, kidney-sparing surgery instead of r…

This phase II trial tested a combination of three chemotherapy drugs (nab-paclitaxel, cisplatin, and gemcitabine) in 42 people with metastatic pancreatic cancer that had not been treated before. The main goal was to see how many patients were alive after 12 months. The study also…

This Phase 3 trial tested a new combination of chemotherapy drugs—irinotecan liposome, oxaliplatin, 5-fluorouracil, and leucovorin—against the standard treatment (nab-paclitaxel plus gemcitabine) in 770 people with metastatic pancreatic cancer who had not received prior chemother…

This pilot study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 20 adults with liver cancer that could not be surgically removed. The goal was to see if the treatment is safe and to measure how long patients survive. The approach aims to d…

This study tested a triple combination treatment for advanced liver cancer that has spread. It combines a procedure called TACE (which blocks blood flow to the tumor) with immunotherapy drugs (PD-1/PD-L1 inhibitors) and targeted therapies (VEGF-TKI or bevacizumab). The goal is to…

This study tested a three-pronged approach for intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), immunotherapy drugs that help the immune system fight cancer, and targeted drugs that stop blood vessel growth. Over 900 patients participated. …

This study looked at 200 people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. Researchers compared two second-line options: a PD-1 inhibitor combined with either lenvatinib or regorafenib. The goal was to see which combo works bet…

This study tested a new treatment for advanced liver cancer that has spread into the major blood vessels of the liver. Thirty patients received a special type of radiation along with an immunotherapy drug called tislelizumab. The goal was to see if this combination could help pat…

This early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…

This study tested a mix of three drugs—trastuzumab deruxtecan (a targeted therapy), nivolumab (an immunotherapy), and chemotherapy—in 30 people with untreated HER2-low stomach or gastroesophageal junction cancer. The goal was to first find a safe dose and then see how well it shr…

This early-phase study tested two immunotherapy drugs (spartalizumab and canakinumab) given before surgery to 17 people with localized clear cell kidney cancer. The main goal was to see if this approach was safe and did not delay surgery. The study also looked at how the drugs af…

This study tested a chemotherapy cocktail called FOLFIRINOX in 72 patients aged 70 or older with metastatic pancreatic cancer. The doses were adjusted based on each person's genetics to reduce side effects while still fighting the tumor. The goal was to see if this approach could…

This phase 2 trial tested the drug sunitinib in 21 patients with kidney cancer that had spread to the brain. The goal was to see if the drug could shrink brain tumors by blocking blood flow and cell growth. Researchers measured how many patients had a response after two treatment…

This Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced bile duct cancer live longer. The study enrolled 158 Chinese adults with cancer that had spread or could not be removed by…

This early-phase study tested a new treatment using immune cells from cord blood, modified to target a protein called Claudin18.2 found on some cancer cells. Ten adults with advanced stomach or pancreatic cancer who had no other options received these cells to find the safest dos…

This phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…

This study tested a new drug called HCW9218 in 21 people with advanced pancreatic cancer that had stopped responding to standard treatments. The drug is designed to boost the immune system and block a protein that helps tumors grow. The main goals were to check safety and find th…

This study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…

This early-phase trial tested a new type of radiation called carbon ion therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. Fourteen participants received increasing doses of carbon ion radiation along with chemotherapy. The main goal was…

This study tested whether a drug called ruxolitinib can reduce abnormal breast cells in people with high-risk or precancerous breast conditions like DCIS or atypical hyperplasia. Half of the 84 participants took ruxolitinib for about 15 days before surgery, and the other half too…

This study tested a combination of two drugs, AZD6738 and olaparib, in 123 women with recurrent ovarian cancer. The goal was to see if the combo is safe and how well it shrinks tumors or delays cancer growth. Participants had either platinum-sensitive or platinum-resistant cancer…

This study tested a new way to destroy small liver tumors using two microwave antennas at once, compared to the standard single antenna method. Twenty patients with small hepatocellular carcinoma (liver cancer) were treated. The goal was to see if the two-antenna approach could m…

This study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…

This study tested a special type of radiofrequency ablation using two cooled needles that also release saline to treat liver cancer that came back after chemoembolization. The goal was to see if this technique could better destroy the tumor and prevent it from growing back. One h…

This study looked at how safe and effective the drug Cabozantinib is for people aged 70 and older with advanced kidney cancer. Researchers tracked side effects and tumor response in 100 participants. The goal was to see if this treatment works well in older patients who have alre…

This phase 2 trial tested darolutamide, a drug that blocks male hormones, in 57 people with a rare type of salivary gland cancer that has male hormone receptors. Some patients received darolutamide alone, while others also got goserelin to lower hormone levels. The goal was to se…

This early-phase trial tested a combination of two targeted drugs (regorafenib and nivolumab) plus standard chemotherapy in 30 adults with advanced or recurrent stomach, gastroesophageal junction, or esophageal adenocarcinoma that could not be surgically removed. The goal was to …

This study tested giving chemotherapy before a less invasive surgery for early rectal cancer. The goal was to see if this approach could allow patients to keep their rectum instead of needing major surgery. 58 people took part, and the treatment was considered successful if at le…

This study tested a combination of two oral drugs, ribociclib and everolimus, in 12 people with metastatic pancreatic cancer that had stopped responding to standard chemotherapy. The goal was to find the right dose and see if it could slow tumor growth. The trial was small and ea…

This study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection …

This phase 3 trial tested whether a surgical procedure called laparotomy plus heated chemotherapy (HIPEC) could improve outcomes for colorectal cancer patients at high risk of cancer spreading in the abdomen. 150 patients who had already undergone surgery and chemotherapy were ra…

This Phase 2 trial tested a combination of three treatments—local chemotherapy delivered via beads into the liver, a targeted drug called apatinib, and an immunotherapy (PD-1 antibody)—in 20 patients with advanced bile duct cancer that had worsened after standard first-line chemo…

This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…

This early-phase trial tested two drugs—binimetinib and hydroxychloroquine—in 34 people with a specific type of advanced pancreatic cancer (KRAS-mutant) that had spread. The goal was to find the safest dose of hydroxychloroquine when used with binimetinib, and to see if the combi…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This phase 2 trial tested adding the immunotherapy drug durvalumab to a standard chemotherapy regimen (docetaxel, oxaliplatin, S-1) before and after surgery in 68 patients with resectable stomach or gastroesophageal junction cancer. The main goal was to see how many patients had …

This study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…

This phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…

This phase 3 trial tested whether a single injection of radioactive lipiodol (Lipiocis) into the liver artery could prevent hepatocellular carcinoma from coming back after surgery or ablation. The study enrolled 73 adults with cirrhosis and one or two liver tumors that had been s…

This study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…

This phase II study tested whether adding trastuzumab (a targeted therapy) to standard chemotherapy could help people with advanced stomach or gastroesophageal junction cancer. Unlike typical patients, these participants had tumors that tested negative for HER2 in tissue but posi…

This study tested an experimental immunotherapy called indoximod added to standard chemotherapy (gemcitabine and nab-paclitaxel) in 157 people with metastatic pancreatic cancer. The goal was to find a safe dose and see if the combination helps people live longer. The trial has co…

This early-phase study tested a new drug called gevokizumab alongside standard cancer treatments in 167 adults with advanced colorectal, stomach, or kidney cancer that had spread. The goal was to find a safe and active dose and see if the combination could help control the diseas…

This study tested a new way to reconnect the pancreas to the intestine during Whipple surgery for certain cancers. The new method uses a stent and wraps the connection with omentum (fatty tissue) to try to prevent leaks. 48 patients were split into two groups to compare the new t…

This early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …

This early-phase trial tested an experimental oral drug called IOA-289 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in 16 people with metastatic pancreatic cancer. The main goal was to check safety and find the right dose. Researchers also looked at how th…

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …

This completed Phase 2 trial tested whether a special DNA-based test could predict how well patients with stomach or rectal cancer respond to immunotherapy (tislelizumab) combined with chemotherapy and/or radiation. 189 adults with advanced cancer participated. The goal was to se…

This phase 3 trial tested whether adding radiofrequency ablation (RFA) to standard transarterial chemoembolization (TACE) improves outcomes for people with intermediate-stage liver cancer. 241 participants with 2-10 liver tumors were randomly assigned to receive either TACE alone…

This study tested a combination of two oral chemotherapy drugs, vemurafenib and sorafenib, in 10 people with advanced pancreatic cancer that has a specific genetic change called a KRAS mutation. All participants had already tried at least two standard treatments without success. …

This study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…

This phase II trial tested whether giving the immunotherapy drug tislelizumab, alone or combined with the targeted therapy lenvatinib, before surgery could help shrink liver tumors in 36 patients with resectable hepatocellular carcinoma. The main goal was to see if at least half …

This study tested whether measuring drug levels in the blood can help doctors adjust doses of two common kidney cancer medications, sunitinib and pazopanib. The goal was to see if this personalized approach reduces side effects and keeps the cancer from growing longer than the st…

This study tested a new ovarian stimulation protocol using degarelix (a drug typically used for prostate cancer) to help breast cancer patients preserve their fertility before chemotherapy. The goal was to keep estrogen levels low while still collecting enough eggs for freezing. …

This study tested two different treatment plans for people with a specific type of pancreatic cancer that is on the edge of being removable by surgery. 130 patients received either chemotherapy alone or chemotherapy plus radiation before surgery. The goal was to see which approac…

This study looked at 60 people with advanced pancreatic body or tail cancer that couldn't be removed by surgery. It compared a targeted treatment called splenic artery infusion chemotherapy (SAIC), which delivers chemo directly to the tumor's blood supply, with standard chemo giv…

This completed Phase 2 study tested a combination of chemotherapy (FOLFIRI) and radiation with 5-fluorouracil in 63 patients with gastric cancer. The treatment was given either before or after surgery to remove the tumor. The goal was to see if this approach is feasible and less …

This study tested whether giving higher doses of two chemotherapy drugs (epirubicin and docetaxel) along with a drug to boost immune recovery (pegfilgrastim) could help women with advanced or inflammatory breast cancer. 93 women took part. The goal was to see how well the treatme…

This phase II trial tested whether adding metformin, a common diabetes drug, to standard chemotherapy could help control advanced ovarian, fallopian tube, or primary peritoneal cancer. 111 participants received either metformin or a placebo alongside chemotherapy, followed by mai…

This study tested a drug called niraparib in 32 people with advanced pancreatic cancer that has certain gene changes (like BRCA). The goal was to see if the drug could slow down or stop the cancer from growing. While not a cure, it offers a targeted treatment option for patients …

This study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…

This study compared two radiation therapy schedules for men with intermediate- or high-risk prostate cancer. One group received fewer, higher-dose radiation sessions (hypofractionated), while the other received standard daily doses. Both groups also received hormone therapy. The …

This study tested a procedure called selective internal radiation therapy (SIRT) using Y-90 resin microspheres (SIR-Spheres) in one patient with liver cancer that could not be removed by surgery. The goal was to see if a flexible dosing approach could improve outcomes like tumor …

This phase 2 trial tested a combination of chemotherapy drugs given directly into the liver artery for people with pancreatic cancer that had spread only to the liver and stopped responding to standard treatment. The 40 participants received a mix of oxaliplatin, irinotecan lipos…

This study tested a new cancer drug called ERAS-007, given by mouth, together with other targeted therapies in 101 people with advanced colorectal or pancreatic cancers that have certain gene changes. The main goals were to check safety, find the best dose, and see how the drugs …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…

This study tested whether giving the immunotherapy drug pembrolizumab before and after a standard tumor-destroying procedure (ablation) could improve outcomes for 30 people with early-stage liver cancer. The goal was to see if the combination could shrink tumors and delay recurre…

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This study tested a new combination of two drugs (IBI310 and sintilimab) against the standard drug sorafenib for people with advanced liver cancer who had not received prior treatment. The goal was to see if the combination could help patients live longer or shrink tumors more ef…

This early-stage study tested a new drug called cabotamig in 33 adults with advanced cancers of the digestive system (like colon, pancreas, or liver) that had stopped responding to standard treatments. The goal was to see if the drug is safe and how it affects the body and tumors…

This early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…

This small pilot study tested a combination of two drugs, alectinib and nivolumab, in 5 adults with advanced liver cancer that had not responded to standard treatments. The goal was to see if the combination could shrink tumors. Because it was a very early phase 1 trial with very…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…

This study compared two chemotherapy regimens (FOLFOX and CarboP-pacliT) given with radiation before surgery for esophageal or junction cancer. 106 patients were enrolled to see which treatment leads to better tumor removal and fewer serious complications. The goal is to help doc…

This study tested an experimental drug called ZN-c3 (azenosertib) in 92 women with a rare and aggressive type of uterine cancer that had come back or not responded to standard treatments. The goal was to see if the drug could shrink tumors and to check its safety. The drug is tak…

This study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shr…

This phase 2 study tested a combination of two drugs, fulvestrant and abemaciclib, in 28 patients with a specific type of uterine cancer that is sensitive to hormones. The goal was to see if the drugs could shrink tumors or stop them from growing. Researchers also tracked side ef…

This early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body h…

This phase 2 study tested a combination of two drugs, durvalumab and SNDX-6352, in 5 people with advanced bile duct cancer that had not spread beyond the liver. Participants first received standard chemo or radiation therapy directly into the liver, then the drug combination. The…

This study collects blood, tissue, and urine from about 589 people with different types of kidney or urinary tract tumors, plus healthy volunteers. Researchers are looking for special DNA markers (methylated DNA) that could help detect these cancers earlier and more accurately. T…

This study tested whether a special PET scan tracer called 18F-DOPA can better detect leftover medullary thyroid cancer in lymph nodes after surgery, compared to standard imaging. Twenty-four adults with elevated thyrocalcitonin levels (a sign of residual disease) received the tr…

This early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…

This study tested a new blood test called EPISPOT to find prostate cancer cells in the blood of 361 men with localized prostate cancer before they received any treatment. The goal was to see if this test could predict remission better than an existing test called CellSearch. The …

This study tested whether a PET scan using a tracer called 18F-FAZA can measure low oxygen levels (hypoxia) in pancreatic cancer. Hypoxia can affect how the cancer grows and responds to treatment. 48 adults with pancreatic cancer received the scan, and researchers also collected …

This study looked at 639 adults with cirrhosis to see if a blood test called mSEPT9 can detect liver cancer (hepatocellular carcinoma) better than the current standard test (AFP). Participants gave an extra blood sample during routine care, and researchers compared how well each …

This study looked at how well a special biopsy method called EUS-FNB can diagnose hard-to-reach tumors in the abdomen, such as those near the bile duct or small intestine. Researchers reviewed data from 131 patients who had this procedure over 10 years. The goal was to see if thi…

This study tested whether a special type of MRI, called perfusion MRI, can help doctors find and diagnose kidney tumors more accurately. 75 people with kidney cancer or suspected kidney tumors took part. The goal was to see if this imaging method could predict tumor type and how …

This study tested a radioactive tracer called [68Ga]FAPI-46, used with a PET scan, to see if it can better detect pancreatic cancer cells. 63 adults with early-stage pancreatic cancer received the tracer before surgery. The goal was to see how well the scan matches the actual can…

This completed study tested whether combining PET/MRI scans with machine learning could better assess how aggressive prostate cancer and other solid tumors are. Researchers enrolled 50 adults with prostate cancer, liver cancer, brain tumors, or kidney cancer. The goal was to see …

This study looked at different ways to take tissue samples from the bile duct during a procedure called ERCP. The goal was to see which method is most accurate for finding cancer. 327 adults with unclear bile duct narrowing took part. Researchers compared several biopsy technique…

This study tested a new ultrasound technique (Side-by-Side Contrast-Enhanced Ultrasound) to see if it could accurately check whether microwave ablation fully destroyed liver tumors just 1-3 days after treatment. Researchers compared it to standard contrast-enhanced ultrasound in …

This study tested a new imaging dye called LS301-IT in 22 women with early-stage breast cancer (DCIS or stage I-II) who were having a partial mastectomy. The dye is injected into a vein before surgery to make cancer cells glow, helping surgeons see and remove them more accurately…

This study tested a new artificial intelligence (AI) algorithm against the standard LI-RADS criteria for diagnosing liver cancer (hepatocellular carcinoma) on CT scans. Researchers enrolled 300 people at risk for liver cancer who had a new liver nodule found on ultrasound. The go…

This completed study tested whether a special type of MRI (multiparametric MRI) can accurately tell the difference between benign and malignant small kidney tumors. About 387 adults with small solid kidney masses (1.5-4 cm) were scanned before surgery or biopsy. The goal was to s…

This study tested a new digital scope called LUMENEYE to see if it can better measure how much a rectal tumor has shrunk after chemotherapy and radiation. 82 patients who were good candidates for organ preservation were included. The goal was to see if the scope could help doctor…

This phase 1 trial tested a new radioactive imaging agent called 64Cu-DOTA-ECL1i to see if it can detect a protein called CCR2 in pancreatic tumors using PET scans. The study involved 69 adults with pancreatic ductal adenocarcinoma at various stages. The goal was to see if the sc…

This study looked at whether MRI can more accurately measure the size of ductal carcinoma in situ (a very early form of breast cancer) compared to standard mammography. Forty women with the condition had MRI scans before surgery. Researchers then compared the MRI results with the…

This study looked at blood samples from 573 people to find new markers that could diagnose liver cancer more accurately. Researchers compared samples from patients with liver cancer, those with other liver conditions, and people with hepatitis infections. The goal is to improve u…

This study looked at whether a breath test could help detect liver fibrosis, cirrhosis, or liver cancer. Researchers collected breath samples from 56 patients with known or suspected liver disease and analyzed them for specific chemical markers. The goal was to see if the test co…

This study tested a new blood test that looks for tiny particles (exosomes) released by cancer cells to find early liver spread in people with pancreatic cancer before they have surgery. The goal is to help doctors decide the best treatment plan by identifying patients at high ri…

This completed study tested a new blood test that looks for tiny particles called exosomal microRNAs to detect intrahepatic cholangiocarcinoma, a rare and aggressive liver cancer. Researchers analyzed blood samples from 535 adults to see how accurately the test could identify can…

This study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…

This study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…

This study looked at whether giving the Gardasil 9 HPV vaccine to women at the same time as surgery for abnormal cervical cells (CIN) can help clear the virus and prevent future infections. About 1,100 women aged 18-55 took part. The goal was to see if the vaccine reduces the cha…

This trial compares two minimally invasive surgical techniques for removing the lower part of the stomach in people with gastric cancer: laparoscopy-assisted distal gastrectomy (LADG) and totally laparoscopic distal gastrectomy (TLDG). The goal is to see which approach leads to b…

This study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…

This study tested whether a remote nutrition coaching program is practical and well-liked by people with pancreatic cancer who are undergoing chemotherapy. Forty participants were asked to complete online food questionnaires and attend coaching sessions over 12 weeks. The goal wa…

This study tested whether a very low dose of apalutamide, taken for 3-4 weeks before prostate removal surgery, could lower PSA levels in 34 men with early-stage prostate cancer. The goal was to see if the drug blocks testosterone's effect on cancer growth. If it works, it might o…

This study tests a 10-week, remotely supervised strength training program for endometrial cancer survivors living in rural or underserved areas. The goal is to see if the program is practical and helps improve physical function and quality of life. Participants exercise twice a w…

This study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…

This pilot study tested a plastic stent with a retrieval string to drain bile in 40 people with resectable bile duct cancer. The goal was to see if the stent could safely reduce bile buildup before surgery. Researchers measured serious complications and how well the stent worked.

This study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…

This study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…

This study tested whether a temporary stent placed inside the bowel could replace a traditional ileostomy (a bag outside the body) after rectal cancer surgery. 570 patients at high risk for leaks were randomly assigned to either the stent or ileostomy. The goal was to see if the …

This study tested whether using a 3D model of a patient's kidney before surgery could shorten the time needed for robotic-assisted partial nephrectomy (removing a kidney tumor). 370 adults with small kidney tumors took part. The goal was to see if better planning with 3D imaging …

This completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults…

This pilot study tested whether spray cryotherapy (freezing the tumor from inside the esophagus) can quickly improve swallowing in 15 patients with advanced esophageal cancer who were about to start chemotherapy and radiation. The goal was to ease difficulty swallowing sooner tha…

This study tested whether a supplement made from muscadine grapes could reduce fatigue and improve quality of life in 106 men with prostate cancer who were already receiving hormone therapy (androgen deprivation therapy). Participants took either the grape extract or a placebo fo…

This study tested two behavioral programs—coping skills training and general health education—to see which better improves well-being in people with ongoing pain after breast cancer surgery. About 316 participants who had surgery for breast cancer or precancerous conditions took …

This study compared two types of nipple-sparing mastectomy for breast cancer: one done with a robot and the other with traditional open surgery. 82 women took part, and the main goal was to see which approach led to higher patient satisfaction. The trial also looked at recovery t…

This study looked at whether mindfulness exercises can lower stress and improve communication between patients with liver disease and their doctors. 56 adults took part, answering surveys about their stress, anxiety, and how well they felt they could share decisions with their he…

This study looked at 98 adults who had kidney removal surgery to see which pain-blocking method works better: a paravertebral block or an external oblique intercostal block. Both are injections that numb nerves to reduce pain after surgery. The goal was to find which one leads to…

This study tested whether giving a single dose of pregabalin before a liver cancer ablation procedure can reduce pain afterward. 70 adults with liver cancer were randomly assigned to receive either pregabalin or a placebo before their procedure. The main goal was to measure pain …

This study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The…

This study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …

This study looked at adrenal gland tumors to understand why they form, why some release extra hormones, and why some are cancerous. Researchers studied 690 people with known or suspected adrenal tumors. Participants underwent tests like blood draws, imaging scans, and urine colle…

This completed study from Minia University looked at 200 patients with autoimmune thyroiditis (an inflamed thyroid) who had thyroid surgery. The goal was to see how often thyroid cancer is found by accident when examining the removed tissue. Researchers checked for cancer in pati…

This study investigates whether a simple blood test (liquid biopsy) can track how advanced non-small cell lung cancer changes during immunotherapy or targeted therapy. Researchers will analyze tumor DNA circulating in the blood to see if it can predict treatment response and dete…

This completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…

This study investigates whether having an empty bladder reduces movement of the mesorectum (tissue around the rectum) during radiotherapy for rectal cancer. About 50 adults with rectal cancer receive planning CT scans and weekly CBCT scans under both empty and full bladder condit…

This study looked at 153 people having liver cancer surgery to see if the type of anesthesia they received affected their recovery and immune response. Researchers compared different anesthesia methods and measured blood markers related to inflammation and immune cell activity. P…

This pilot study tested whether a rapid lab test called frozen section analysis, done during thyroid surgery, can help surgeons decide how many lymph nodes to remove from the neck. The study included 66 adults with low-risk thyroid cancer and no signs of spread before surgery. Th…

This completed study looked at a new antibody called anti-SIRPα as a potential immunotherapy for liver cancer. Researchers used blood and tissue samples from 30 liver cancer patients to see how the antibody affects immune cells. The goal was to understand whether blocking the SIR…

This early-phase trial tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 patients with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side eff…

This completed study examined whether a specific variation in the VEGF gene (rs699947) is linked to a higher risk of developing kidney cancer in people who have received a kidney transplant. Researchers analyzed DNA from 272 transplant patients, some of whom had kidney cancer. Th…

This completed study looked at 3000 patients having liver surgery to see if considering both medical and social factors could reduce how long they stay in the hospital. Researchers tracked things like complications and readmissions. The goal is to find ways to improve recovery an…

This study tested a prediction tool (nomogram) to see if it could forecast how patients with metastatic clear cell renal cell carcinoma respond to the targeted therapy sunitinib. Researchers looked at 45 patients who had their kidney removed and were treated with sunitinib as the…

This study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…

This completed study analyzed tissue samples from 108 breast cancer patients to identify proteins linked to early cancer invasion. The goal was to find markers that could help assess the risk of tumor spread in patients without lymph node involvement. Researchers focused on listi…

This study looked at 100 patients who had sleeve gastrectomy for severe obesity. Researchers checked how many developed Barrett's esophagus, a condition that can lead to esophageal cancer, five or more years after surgery. They also examined whether routine endoscopy (a camera te…

This study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…

This study tested three types of messages to encourage genetic testing in 1,283 people at risk for hereditary breast and ovarian cancer. Participants received an electronic health record message, then a text message, then a doctor's reminder if needed. The goal was to see which a…

This study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…

This study looked at 180 people with liver cancer (hepatocellular carcinoma) who also had cirrhosis caused by either fatty liver disease or alcohol use. Researchers compared immune cells and gut bacteria in the liver to understand why cancer develops. The goal was to gather knowl…

This completed study created a registry of 28 patients with TFE renal cell carcinoma, a rare kidney cancer. Researchers collected medical data, tumor samples, and images to better understand the disease. The goal is to use this information to guide future research and develop mor…

This study reviewed medical records of 494 adults with advanced kidney cancer who received immunotherapy as their first treatment. Researchers looked at how long patients stayed on treatment, how they responded, and survival rates. The goal was to understand which treatment combi…

This study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.

This study followed 623 adults in France with advanced kidney cancer who were starting treatment with the immunotherapy drugs nivolumab (with or without ipilimumab) for the first time. Unlike a clinical trial, this was an observational study that simply tracked what happened in e…

This study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…

This study enrolled 200 adults with lung adenocarcinoma that has spread to the bones. Researchers took bone biopsies, scans, and blood tests to measure bone and metabolic markers. The goal is to see if these markers are linked to how long patients live. This is an observational s…

This study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…

This pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.

This study looked at how an experimental drug called SHR3680 affects the way the body processes three other common drugs: digoxin, rosuvastatin, and metformin. Thirty-six men with prostate cancer took SHR3680 along with these drugs to see if there were any interactions. The goal …

This study looked at 10 people with liver cancer (HCC) who were getting a standard treatment called chemoembolization (c-TACE). The goal was to see if mixing the chemotherapy drug doxorubicin with salt water or a contrast dye changes how the drug spreads inside the tumor. Researc…

This early-phase trial tested a fluorescent antibody that attaches to prostate cancer cells. Seven men with moderate- to high-risk prostate cancer received the antibody before robotic prostate removal surgery. The goal was to see if the glowing antibody could help surgeons identi…

This study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…

This study collected information from 733 people with a personal or family history of hereditary stomach cancer. The goal was to better understand how these cancers develop and what genes are involved. Participants provided medical history, blood samples, and genetic testing. The…

This study looked at 24 people with lung or esophageal cancer who received radiation or chemo-radiation near the heart. Participants wore a small heart monitor to catch any heart changes that might otherwise go unnoticed. The goal was to see how often heart problems occur after s…

This study tested a custom-made device called the Breast Cancer Locator (BCL) in 35 women with non-palpable breast cancer. The device helps surgeons see exactly where the tumor is during breast-conserving surgery, with the goal of removing all cancer in one go and reducing the ne…

This completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…

This study created a new tool called the SAH Index to fairly evaluate how well hospitals and surgeons perform gastric cancer surgery. Gastric cancer is serious and often requires major surgery, but comparing results is tricky because patients have different health risks. The rese…

This study looked at how lifestyle factors like obesity and muscle loss affect kidney cancer risk and survival after kidney removal. Researchers collected blood, tissue, and questionnaire data from 161 patients over up to 5 years. The goal was to understand how to personalize tre…

This completed research study collected and stored tumor tissue, blood, and urine samples from 8,000 children and young adults with kidney tumors. The goal was to help scientists study DNA changes and find biomarkers that could improve understanding of these cancers. No treatment…

This study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…

This study looked at whether an AI computer program could suggest cancer treatments that match what experts recommend. Researchers reviewed medical records of 30 people with stomach, colon, or pancreatic cancer. They entered key details into the AI and compared its suggestions to…

This registry followed over 1,000 liver cancer patients who received SIR-Spheres—tiny radioactive beads injected into the liver's blood supply to kill tumors. The goal was to see how this treatment is used in real hospitals and how it affects survival, side effects, and quality o…

This study aimed to improve how doctors predict whether prostate cancer has spread to nearby lymph nodes. Researchers combined patient information, MRI scans, and genetic data from 367 men who had their prostate removed. The goal was to create a more accurate tool to help decide …

This study analyzed data from nearly 3,000 patients who had surgery for esophageal cancer between 2000 and 2010. Researchers looked at factors like patient health, treatment approach, and surgical technique to see what influences cancer recurrence and survival. The goal is to bet…

This study tested a new ultrasound technique called ARFI to measure liver stiffness in 109 people, including healthy volunteers and patients with liver conditions. The goal was to understand normal stiffness values and how they change with disease or treatment. This is an observa…

This study tested whether implanting tiny gold markers near spinal tumors helps deliver radiation more accurately. Researchers also checked if giving slightly more radiation to the nearby esophagus is safe, which might improve tumor control. The study involved 41 adults with vari…

This study tested whether having patients stand during an ultrasound helps doctors see small liver tumors near the diaphragm that are often missed when lying down. Researchers scanned 95 people with confirmed liver lesions in three positions: standing, lying on their back, and ly…

This study looked at whether a software program called Carevive could help patients with advanced kidney cancer track side effects from their oral targeted therapy or immunotherapy. 21 patients used the software to report symptoms and received self-care tips. The goal was to see …

This study tested whether an AI tool can help health providers write medical summaries that are easier for patients to understand. 120 providers were split into two groups: one used the AI tool, the other did not. The goal was to see if AI could improve readability and save time,…

This study tested a new classification system for people whose colorectal cancer has spread only to the liver. Researchers looked at survival rates and compared different patient groups to see if the system helps predict outcomes. The goal is to better identify which patients mig…

This study analyzed data from 1005 liver cancer patients to see who benefits from a treatment called TACE after surgery. Using machine learning, researchers aimed to predict individual patient outcomes. The goal is to help doctors decide whether to recommend TACE or just monitor …

This study tracked 295 adults who had high-risk surgery for stomach, esophagus, pancreas, or liver cancer. Researchers measured quality of life before surgery and again at 6 and 12 months after. They also asked patients and their family members if they regretted the decision to h…

This study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…

This completed study from the University of Aberdeen looked at how dietary fiber supplements might influence prostate cancer. Researchers gave mice different fibers (inulin, pectin, hemp hull) along with stool samples from healthy men over 60. They then measured changes in gut ba…

This study tested 892 African and Asian immigrants for hepatitis B and C to understand how these infections raise the risk of liver cancer. Researchers also checked vaccination rates and tracked new cancer cases over time. No treatment was given; the goal was to gather informatio…

This study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…

This study aimed to find biological markers (biomarkers) in pancreatic tumor cells and blood that could help predict how well a patient might respond to treatment. Researchers analyzed genetic and protein information from tumor samples collected via ultrasound-guided biopsy, as w…

This study looked at 211 people with liver cirrhosis to see which screening method works better for detecting liver cancer: an ultrasound every 6 months or an MRI once a year. Participants received both tests, and researchers measured how often each test correctly found cancer. T…

This study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a tiny radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to treat t…

This study looked at whether giving a short, strong dose of radiation right before surgery is possible for people with pancreatic cancer. Ten patients took part to see if the approach was safe and could help surgeons remove the tumor completely. The main goal was to check for com…

This study tested whether it is safe and possible to collect a blood sample from the portal vein (a major liver blood vessel) during a routine endoscopic ultrasound in 23 people with pancreatic cancer. The goal was to find and count circulating tumor cells (cancer cells in the bl…

This study examined small RNA molecules called microRNAs in tissue samples from 57 people with pancreatic cancer. The samples were collected during a routine endoscopic ultrasound procedure. Researchers aimed to see if certain microRNA patterns are linked to how aggressive the ca…

This study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…

This study looked at 74 people with metastatic colorectal cancer starting their first chemotherapy. Researchers took blood samples early in treatment to measure three markers: CEA, circulating tumor DNA, and total cell-free DNA. The goal was to see if early changes in these marke…

This completed study looked at tumor samples from 687 women with advanced high-grade serous ovarian cancer who were treated with chemotherapy. Researchers examined different types of immune cells in the tumors to see if they were linked to how well patients did. The goal was to b…

This study tested whether it is practical to routinely check ovarian cancer tumors for BRCA gene mutations in the clinic. Researchers enrolled 200 patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. They used blood and tumor samp…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study looked back at the medical records of 500 people with colorectal cancer from two regions in China. Researchers collected information on patients' backgrounds, lifestyle, and treatments to find patterns that affect survival. The goal was to understand regional differenc…

This completed study involved 775 women who had breast-conserving surgery and radiation for breast cancer. Researchers compared different surgery and radiation techniques to see which ones led to less breast hardening (fibrosis) and better cosmetic results. The goal was to find w…

This completed study looked at whether a simple blood test (liquid biopsy) can find genetic markers that predict how well pancreatic cancer treatments work. Researchers analyzed DNA from tumors circulating in the blood of 420 patients with pancreatic cancer. The goal was to disco…

This completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…

This study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…

This study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …

This study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue r…

This completed study from West China Hospital examined tumor tissue from 100 colorectal cancer patients who had already received immunotherapy. Researchers measured levels of a protein called PHGDH to see if it was linked to how well the patients responded to treatment and how lo…

This study tested whether 3D ultrasound can accurately measure kidney and tumor volumes compared to standard CT or MRI scans. 53 adults with chronic kidney disease or kidney tumors participated. Researchers compared 3D ultrasound measurements to those from contrast-enhanced CT or…

This study looked back at medical records of over 1,000 people with rare breast conditions called florid and pleomorphic lobular carcinoma in situ (FLCIS and PLCIS). The goal was to understand how doctors currently diagnose and treat these conditions, since there are no official …

This completed study looked at the medical records of 8 men diagnosed with breast cancer at Methodist Health System. Researchers wanted to understand their demographics, how their disease progressed, and what complications they faced. Because male breast cancer is very rare, this…

This study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…

This study looked at liver cancer cells from 30 patients to understand how they differ from healthy cells. Researchers isolated these cells to create 3D lab models called organoids. The goal was to learn more about the behavior and genetics of liver cancer, not to test a new trea…

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving their first immunotherapy treatment could successfully collect small blood samples at home using a finger-prick method. The goal was to see if this approach is practical and rel…

This completed study looked at 169 patients with a type of liver cancer called intrahepatic cholangiocarcinoma. Researchers used MRI scans and machine learning to measure scar tissue and a protein linked to tumor growth. The goal was to see if these features could predict how lon…

This completed study looked at how kidney cancers are found—either because a patient had symptoms or by chance during a scan for something else. Researchers reviewed 1000 patients who had surgery for kidney lesions in the Czech Republic. The goal was to see which detection method…

This study tested a computer model that helps surgeons decide the best type of surgery for patients with a rare form of liver cancer that has spread into the bile ducts. The model uses patient scans and medical history to recommend whether to remove part of the bile duct or just …

This study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …

This completed Phase 2 trial looked at whether the sentinel lymph node technique—a less invasive way to check if cancer has spread—works for women with multifocal breast cancer (more than one tumor in the same breast). 216 women with early-stage, node-negative multifocal breast c…

This study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…

This study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…

This study looked at how safe and effective a combination of two drugs (Atezolizumab and Bevacizumab) is for people with liver cancer and cirrhosis, compared to standard pills (tyrosine kinase inhibitors). Researchers followed 38 patients to see how long they lived and how their …